EGCG (Green Tea Extract)

Epigallocatechin-3-gallate (EGCG) is the most abundant and pharmacologically studied catechin in green tea, derived from the leaves of Camellia sinensis. It accounts for approximately 50 percent of the total polyphenol content in green tea and is the compound primarily responsible for the health effects attributed to green tea consumption. In culinary use — brewed tea — EGCG is present at concentrations of roughly 50 to 150 mg per cup, depending on preparation. Green tea extract supplements, however, deliver concentrated doses of 200 to 1,000 mg EGCG or more per serving, representing a qualitatively different exposure profile. The distinction between brewed tea and concentrated extracts is critical to interpreting both the efficacy and safety evidence.

What it is

EGCG is a flavonoid-3-ol polyphenol with eight free hydroxyl groups that confer potent antioxidant activity in vitro. The proposed mechanisms of action are numerous: EGCG inhibits enzymes involved in fat metabolism including catechol-O-methyltransferase (COMT), activates AMPK signalling relevant to energy metabolism, modulates NF-kB and other inflammatory pathways, and interacts with multiple signalling proteins involved in apoptosis and cell proliferation. At the concentrations achieved in most human supplementation studies, the clinical relevance of these mechanisms is not established, and the mechanistic literature substantially overstates what the clinical trial evidence supports.

EGCG is poorly and variably bioavailable orally. Absorption is affected by food intake — systemic EGCG exposure is substantially higher when taken in a fasted state, which has direct implications for both efficacy claims and hepatotoxicity risk discussed below. Bioavailability also varies considerably between individuals, between extract formulations, and between supplement and brewed tea forms. Some commercial preparations use esterified or encapsulated EGCG to improve stability and absorption, though the clinical relevance of these modifications has not been well tested in outcome trials.

The marketing around EGCG is unusually overclaimed even within the supplement category. Fat burning, cancer prevention, and anti-ageing effects are widely promoted on the basis of mechanistic and preclinical data that have not translated into consistent clinical outcomes. The entry below describes what the human evidence actually shows.

What the evidence shows

Weight management. The largest and most consistently replicated clinical signal for EGCG is a small reduction in body weight in overweight and obese adults. A major limitation across this literature is that many trials include caffeine alongside EGCG, making it difficult to attribute effects specifically to EGCG; trials using EGCG alone have generally shown weaker or null effects. A GRADE-assessed systematic review and meta-analysis of randomised controlled trials (British Journal of Nutrition, 2023) including 38 RCTs found that green tea extract supplementation produced a statistically significant mean reduction in body mass of approximately 0.64 kg (95% CI −0.97 to −0.30) compared with placebo, without significant heterogeneity across studies. This is a modest effect of uncertain clinical significance, and the contribution of caffeine to the pooled estimate cannot be excluded. An average reduction of approximately 0.6 kg is unlikely to be clinically meaningful for most individuals in the context of long-term weight management, and no evidence supports that EGCG produces meaningful sustained weight management outcomes.

Cardiovascular biomarkers. Multiple meta-analyses have examined green tea extract effects on blood pressure, lipids, fasting glucose, and inflammatory markers. Results are generally in a favourable direction but small in magnitude and inconsistent across populations. Blood pressure effects appear more pronounced in hypertensive subgroups than in normotensive individuals. LDL cholesterol reductions are modest and not consistently replicated. These effects are small and unlikely to translate into meaningful reductions in cardiovascular risk. These are biomarker endpoints; no trial has demonstrated that EGCG supplementation reduces incident cardiovascular events.

Cancer prevention. This is the domain with the largest gap between marketing claims and evidence. Mechanistic plausibility for anticancer effects is substantial in vitro and in animal models, where EGCG influences pathways relevant to apoptosis, cell proliferation, and tumour angiogenesis. Observational data from green tea-drinking populations in East Asia have been interpreted as suggesting lower cancer incidence, but these associations are confounded by diet, lifestyle, and other factors, and cannot be attributed specifically to EGCG. Randomised controlled trial evidence for cancer prevention is limited and inconsistent. A meta-analysis including cohort studies and available RCTs found no consistent protective effect across cancer types when evidence quality was assessed rigorously. EGCG cannot be claimed to prevent or treat cancer on the basis of current human clinical evidence, and the gap between mechanistic data and clinical evidence in this domain is one of the largest in the supplement literature.

Cognitive function. Some trials have examined EGCG's effects on cognition and neuroprotection, largely in older populations or populations with metabolic risk factors. Results are inconsistent and derive from small trials. This is an area of active preclinical interest that has not yet produced reliable clinical evidence.

Five questions

Does low status cause harm? EGCG is not an essential nutrient; there is no deficiency state. Low green tea intake or low EGCG exposure does not constitute a nutritional deficiency. The clinical evidence is about the effects of supplemental doses rather than correction of inadequacy.

Does supplementation prevent disease? No. Despite extensive mechanistic research and large marketing claims, no well-designed randomised controlled trial has demonstrated that EGCG supplementation prevents cancer, cardiovascular disease, or any other specific disease. Observational associations in green tea-consuming populations are not attributable to EGCG specifically and are subject to substantial confounding.

Does it affect biomarkers? Yes, in some contexts. Biomarker effects reported across trials include modest reductions in body weight, LDL cholesterol, fasting glucose, blood pressure, and inflammatory markers including C-reactive protein. These changes are generally small, not consistently replicated, and in most cases have not been validated as clinically meaningful surrogates for the outcomes they are proposed to represent. Biomarker changes in fat oxidation studies — including changes in respiratory quotient — are mechanistically plausible but of uncertain clinical significance, and are likely at least partly caffeine-mediated.

Does it help clinical populations? The clearest potential signal is in overweight and obese individuals, where weight effects are most consistent. There is some evidence of cardiovascular biomarker benefit in hypertensive individuals. No clinical benefit has been demonstrated in people with established cancer, cardiovascular disease, or cognitive impairment. The evidence does not support EGCG as an adjunct treatment in any clinical disease population on current data.

Does it benefit healthy individuals? The modest weight effect observed in pooled analysis appears primarily in overweight rather than healthy-weight individuals. For healthy individuals with no metabolic risk factors, evidence of benefit across any outcome domain is weak. The antioxidant effects measurable in laboratory assays do not translate predictably into functional benefit in healthy people.

Individual variation

The most clinically important source of individual variation for EGCG is genetic susceptibility to hepatotoxicity. The HLA-B35:01 allele has been found in approximately 72 percent of confirmed green tea extract-associated drug-induced liver injury cases, compared with a population prevalence of 5 to 15 percent. This represents a meaningful genetic risk factor for an idiosyncratic hepatotoxic reaction. The allele is not routinely tested, but individuals with a personal or family history of unexplained liver enzyme elevations, or with known HLA-B35:01 status, should be aware of this interaction.

Fasting state is the second critical determinant of individual risk. EGCG taken on an empty stomach achieves systemic exposure approximately four-fold higher than when taken with food. This substantially increases both potential activity and hepatotoxicity risk, and regulatory guidance and clinical evidence consistently recommend supplement consumption with food.

Body weight also appears to modify both the potential for benefit and liver injury risk. EFSA's analysis found liver effects more pronounced in higher-BMI individuals in the Minnesota Green Tea Trial — notable because this is exactly the population most likely to be using high-dose EGCG for weight management.

Sex and hormonal status are relevant. Most cases of clinically apparent green tea extract hepatotoxicity have been reported in middle-aged women, who are also the population most likely to use high-dose extracts for weight control. Whether this reflects greater hormonal susceptibility, greater product use, or a combination is not established.

Caffeine sensitivity influences the thermogenic and metabolic effects attributed to EGCG-caffeine combination products. Individuals who are habitual caffeine consumers may show reduced thermogenic response compared with caffeine-naive individuals.

Testing and status assessment

There are no relevant clinical tests for EGCG status. Liver function tests — specifically ALT — are the monitoring parameter of most practical relevance for anyone using high-dose EGCG supplements. EFSA and USP guidance suggests monitoring liver enzymes with high-dose supplementation, though this is not common practice in supplement users. Any unexplained ALT elevation in someone using green tea extract should prompt immediate discontinuation.

Safety

The safety profile of EGCG is one of the most carefully characterised of any supplement in this category, and the findings are more concerning than most marketing materials acknowledge. Risk is substantially increased when taken in a fasted state. The critical distinction is between brewed green tea and concentrated supplement extracts.

Brewed green tea at typical intakes — up to five or more cups per day delivering up to 700 mg EGCG — is considered generally safe and has not been consistently associated with hepatotoxicity in the clinical literature. Dietary intake at these levels is considered to correspond to an established pattern of safe traditional use.

Concentrated green tea extract supplements represent a different risk profile. The EFSA scientific opinion (2018) concluded that doses at or above 800 mg EGCG per day from food supplements induce statistically significant increases in serum transaminases compared with placebo, based on evidence from interventional trials. Over 200 case reports of green tea-associated liver injury have been published, with the pattern being predominantly hepatocellular, most commonly presenting as an acute viral hepatitis-like syndrome with jaundice and markedly elevated aminotransferases, typically resolving on discontinuation. The NIH LiverTox database assigns green tea a Likelihood Score A — well-established cause of clinically apparent liver injury. Rechallenge cases demonstrating recurrence of liver injury on reintroduction provide particularly strong evidence of causality.

The hepatotoxicity is primarily idiosyncratic rather than dose-dependent in a simple linear sense. The HLA-B35:01 allele is present in approximately 72 percent of confirmed cases, supporting an immune-mediated mechanism. T-cell responses to EGCG in vitro have been demonstrated in HLA-B35:01-positive donors, further supporting immunological pathogenesis. However, cases have been reported at EGCG intakes as low as 140 mg per day, and individual susceptibility cannot be predicted reliably from dose alone.

Fasting administration significantly amplifies hepatotoxicity risk. EGCG bioavailability is approximately four-fold higher under fasting conditions due to saturation of first-pass elimination mechanisms, and the FDA has restricted further human studies using fasting-state EGCG administration for this reason. Regulatory guidance consistently recommends consumption with food.

The EU has imposed mandatory labelling requirements and an 800 mg per day ceiling for EGCG from food supplements since 2022, with warnings required for children, pregnant and breastfeeding individuals, and against fasted consumption. USP derived a safe intake level of 338 mg EGCG per day for bolus supplement doses.

EGCG is contraindicated in individuals with pre-existing liver disease. Caution is warranted in pregnancy and breastfeeding — safety data are absent and the hepatotoxicity concern is sufficient to advise avoidance. Interactions with warfarin and other anticoagulants are possible through EGCG's effects on vitamin K absorption and platelet function, based on mechanistic and limited clinical data; the magnitude of risk is not well quantified. Interactions with certain chemotherapy agents and drugs metabolised via CYP450 pathways have been proposed but not clinically characterised.

What can reasonably be concluded

EGCG from green tea extract has a genuine but modest and largely clinically unvalidated evidence base. The most defensible claim is a small reduction in body weight in overweight adults in pooled analysis, which is likely at least partly attributable to caffeine co-administration rather than EGCG alone. Cardiovascular and metabolic biomarker effects exist but are small, inconsistent, and not validated as clinical outcome surrogates. Cancer prevention claims are not supported by randomised controlled trial evidence and represent one of the largest gaps between mechanistic hypothesis and clinical outcome data in the supplement literature.

The safety concern is the defining feature of EGCG that separates it from most other polyphenol supplements. High-dose supplement use carries a well-characterised idiosyncratic hepatotoxicity risk that has attracted formal regulatory attention in Europe and the United States. The brewed tea versus concentrated extract distinction is essential: traditional green tea consumption at beverage quantities does not carry the same risk as high-dose supplementation. The HLA-B*35:01 genetic susceptibility, fasting-state exposure amplification, and regulatory dose ceiling are all concrete and actionable safety considerations that distinguish this entry from supplements with theoretical safety concerns only.

An Emerging rating reflects the modest and contextually limited clinical evidence. The safety profile adds an additional layer of complexity not present in most other longevity or metabolic health compounds, and warrants explicit attention in any supplementation decision.

Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.